| Effect |
Allele / genotype (individuals studied) |
References |
| Bacterial infections |
HLA-E*01:01, 01:01 in donor
(77 unrelated donor-recipient pairs identically matched for HLA class I and II alleles) |
[26] |
| Transplant related mortality at day 180 |
HLA-E*01:01, 01:01 in donor
(77 unrelated donor-recipient pairs identically matched for HLA class I and II alleles) |
[26] |
| Protection from aGvHD |
HLA-E*01:03, 01:03 either in donor or in recipient
(187 HLA-identical sibling pairs) |
[28] |
| Protection from TRM at day 180 |
HLA-E*01:03, 01:03 either in donor or in recipient
(187 HLA-identical sibling pairs) |
[28] |
| Higher probability of overall survival |
HLA-E*01:03, 01:03 in patients
(83 HLA-matched donor-recipient pairs) |
[29] |
| Disease free survival |
HLA-E*01:03, 01:03 in patients
(83 HLA-matched donor-recipient pairs) |
[29] |
| Decreased incidence of transplant related mortality |
HLA-E*01:03, 01:03 in patients
(83 HLA-matched donor-recipient pairs) |
[29] |
| Higher risk of GvHD |
HLA-E*01:01 and 01:03 unmatched in donor and recipient
(100 allogeneic donor-recipient pairs) |
[30] |
| Higher survival rate |
Homozygotes HLA*01:03, 01:03
(100 allogeneic donor-recipient pairs) |
[30] |
| Decreased risk of aGvHD (II-IV) |
HLA-E*01:03, 01:03 in donors
(121 unrelated donor-recipient pairs) |
[31] |
| Decreased risk of overall aGvHD (cumulative incidence at 3 years) |
HLA-E*01:03, 01:03 in donors
(102 unrelated donor-recipient pairs) |
[31] |
| Higher risk of relapse (cumulative incidence at 3 years) |
HLA-E*01:03 in donors
(124 unrelated donor-recipient pairs) |
[31] |
| TRM (cumulative incidence at 189 days) |
HLA-E*01:03, 01:03 in donors was a risk factor, whereas the presence of HLA-E*01:01 alleles were protective
(124 unrelated donor-recipient pairs) |
[31] |
| Lower risk of aGvHD and cGvHD |
HLA-E*01:03, 01:03 in patients
(56 HLA-E matched donor-recipient pairs) |
[32] |
| Improved overall survival |
HLA-E*01:03, 01:03 in patients
(56 HLA-E matched donor-recipient pairs) |
[32] |
| No effect |
HLA-E*01:03, 01:03 in patients and HLA-E*01:01 in donors
(116 HLA-matched unrelated donors) |
[82] |
| Risk of cGvHD development |
MICA-129 Val/Val in recipients
(211 HLA-identical HSCT sibling pairs) |
[65] |
| Higher incidence of disease relapse |
MICA-129 Met/Met in recipients
(211 HLA-identical HSCT sibling pairs) |
[65] |
| Risk of aGvHD |
MICA donor-recipient mismatches
(236 unrelated HSCT donor-recipient pairs) |
[66] |
| Improved overall survival |
MICA and MICBdonor-recipient matches
(44 unrelated HSCT donor-recipient pairs) |
[67] |
| Risk of aGvHD |
14 bp del/del HLA-G genotype (position+2961 of 3’ UTR) in recipients (53 patients of allo-BMT) |
[81] |
| Risk of aGvHD |
14 bp del/del HLA-G genotype (position+2961 of 3’ UTR) in donors (unrelated HSCT donor-recipient pairs) |
[83] |
| Decrease in the overall and disease-free survival |
14 bp ins/ins HLA-G genotype in recipients
(47 recipients for allo-HSCT receiving MTX
therapy and their donors) |
[80] |
